AstraZeneca (AZN LN) - Q4 (USD): Core EPS 2.12 (exp. 2.14), Revenue 15.5bln (exp. 15.46bln), guides initial FY26 revenue up by mid-to-high single digit and core EPS up by double-digit percentage

• Q4 Imfinzi revenue USD 1.75bln (exp. 1.61bln).
• FY25 oncology revenue USD 25.62bln (prev. 7.03bln Y/Y)
• Co. gets CDSCO approval for Durvalumab in India.

AstraZeneca's Q4 results slightly missed expectations on core EPS and revenue, indicating potential short-term pressure on the stock. However, the guidance for FY26 shows confidence with a mid-to-high single-digit revenue increase and a double-digit percentage growth in core EPS, which suggests management's optimism about future performance. This divergence may create mixed sentiment in the market, with a focus on longer-term growth prospects over the immediate miss.